| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA990009658380403321 |
|
|
Autore |
Mazzolani, Ferderico M. |
|
|
Titolo |
The development of innovative approaches for the designof steel and compositesteel-concrete structural systems : the line 5 of the ReLUIS-DPC 2005-2008 project / Federico M. Mazzolani, Riccardo Zandonini editors |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Napoli : Doppiavoce, c 2011 |
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Descrizione fisica |
|
|
|
|
|
|
Altri autori (Persone) |
|
|
|
|
|
|
Locazione |
|
|
|
|
|
|
Collocazione |
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
|
|
|
|
|
|
|
2. |
Record Nr. |
UNINA9910573096703321 |
|
|
Titolo |
Carbon monoxide in drug discovery : basics, pharmacology, and therapeutic potential / / edited by Leo E. Otterbein, Binghe Wang |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Hoboken, New Jersey : , : John Wiley & Sons, Inc., , [2022] |
|
©2022 |
|
|
|
|
|
|
|
|
|
ISBN |
|
1-119-78343-7 |
1-119-78342-9 |
|
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (1005 pages) |
|
|
|
|
|
|
Collana |
|
Wiley Series in Drug Discovery and Development Ser. |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
|
|
|
|
|
Nota di contenuto |
|
Intro -- Carbon Monoxide in Drug Discovery -- Contents -- List of Contributors -- Preface: Carbon Monoxide: Promises and Challenges in Its Pharmaceutical Development -- Section I General Background and Physiological Actions -- 1 Endogenous CO Production in Sickness and in Health -- 2 Molecular Mechanisms of Actions for CO: An Overview -- 3 Pharmacokinetic Characteristics of Carbon Monoxide -- 4 Carbon Monoxide and Energy Metabolism -- 5 Role of CO in Circadian Clock -- 6 Carbon Monoxide and Mitochondria -- 7 Carbon Monoxide, Oxygen, and Pseudohypoxia -- 8 Nitric Oxide in Human Physiology: Production, Regulation, and Interaction with Carbon Monoxide Signaling -- 9 When Carbon Monoxide Meets Hydrogen Sulfide -- 10 Biliverdin and Bilirubin as Parallel Products of CO Formation: Not Just Bystanders -- Section II Delivery Forms -- 11 Delivery Systems and Noncarrier Formulations -- 12 Metal-Based Carbon Monoxide-Releasing Molecules (CO-RMs) as Pharmacologically Active Therapeutics -- 13 Organic CO Donors that Rely on Photolysis for CO Release -- 14 Organic Carbon Monoxide Prodrugs that Release CO Under Physiological Conditions -- 15 Targeted Delivery of Carbon Monoxide -- 16 Anesthesia-Related Carbon Monoxide Exposure -- 17 Natural Products that Generate Carbon Monoxide: Chemistry and Nutritional Implications -- Section III Carbon Monoxide Sensing and Scavenging -- 18 Fluorescent Probes for Intracellular Carbon Monoxide Detection -- Section IV Therapeutic |
|
|
|
|
|
|
|
|
|
|
Applications -- 19 CO in Solid Organ Transplantation -- 20 Carbon Monoxide in Lung Injury and Disease -- 21 Carbon Monoxide in Acute Brain Injury and Brain Protection -- 22 CO as a Protective Mediator of Liver Injury: The Role of PERK in HO-1/CO-Mediated Maintenance of Cellular Homeostasis in the Liver -- 23 CO and Cancer -- 24 CO and Diabetes -- 25 Carbon Monoxide and Acute Kidney Injury. |
26 CO as an Antiplatelet Agent: An Energy Metabolism Perspective -- 27 CO in Gastrointestinal Physiology and Protection -- 28 Carbon Monoxide and Sickle Cell Disease -- 29 CO and Pain Management -- 30 Clinical Trials of Low-Dose Carbon Monoxide -- Index -- EULA. |
|
|
|
|
|
| |